Evaluating apheresis platelets at reduced dose as a contingency measure for extreme shortages
Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Study design and methods Using production figures, we mode...
Saved in:
Published in | Transfusion (Philadelphia, Pa.) Vol. 62; no. 1; pp. 173 - 182 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.01.2022
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0041-1132 1537-2995 1537-2995 |
DOI | 10.1111/trf.16723 |
Cover
Abstract | Background
The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.
Study design and methods
Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.
Results
Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.
Conclusion
A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages. |
---|---|
AbstractList | The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.BACKGROUNDThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.STUDY DESIGN AND METHODSUsing production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.RESULTSSplitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.CONCLUSIONA strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages. The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage. Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 10 (~138 ml) and 113 ± 11 × 10 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4. A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages. BackgroundThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.Study design and methodsUsing production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.ResultsSplitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.ConclusionA strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages. Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Study design and methods Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage. Results Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4. Conclusion A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages. |
Author | Davies, Jane New, Helen V. Smethurst, Peter A. Proffitt, Susan Stanworth, Simon J. McAndrew, Margaret Cardigan, Rebecca Procter, Simon Doughty, Heidi |
Author_xml | – sequence: 1 givenname: Peter A. orcidid: 0000-0001-6459-1637 surname: Smethurst fullname: Smethurst, Peter A. email: peter.smethurst@nhsbt.nhs.uk organization: NHS Blood and Transplant – sequence: 2 givenname: Margaret surname: McAndrew fullname: McAndrew, Margaret organization: NHS Blood and Transplant – sequence: 3 givenname: Susan surname: Proffitt fullname: Proffitt, Susan organization: NHS Blood and Transplant – sequence: 4 givenname: Simon surname: Procter fullname: Procter, Simon organization: NHS Blood and Transplant – sequence: 5 givenname: Jane surname: Davies fullname: Davies, Jane organization: NHS Blood and Transplant – sequence: 6 givenname: Helen V. surname: New fullname: New, Helen V. organization: NHS Blood and Transplant – sequence: 7 givenname: Simon J. surname: Stanworth fullname: Stanworth, Simon J. organization: Oxford University Hospitals NHS Foundation Trust – sequence: 8 givenname: Heidi surname: Doughty fullname: Doughty, Heidi organization: NHS Blood and Transplant – sequence: 9 givenname: Rebecca surname: Cardigan fullname: Cardigan, Rebecca organization: University of Cambridge |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34757639$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtLLDEQhYMoOj4W_gEJuNFFax7TyfRSxBcIguhSQnWnoi3dnTFJ3-v8e6MzbkQLQkHxnUM4Z5usD35AQvY5O-F5TlNwJ1xpIdfIhJdSF6KqynUyYWzKC86l2CLbMb4yxkTF-CbZklNdaiWrCXm6-AfdCKkdninMXzBgbCOdd5CwwxQpJBrQjg1aan1ECvlEGz98CnBoFrRHiGNA6nyg-J4C9kjjiw8JnjHukg0HXcS91d4hj5cXD-fXxe3d1c352W3RyFLKwipktbb51aVis1LVGqzAGqrZVNQcXMksSOsEz2c91Q6k4kKDc5oJJ6XcIUdL33nwbyPGZPo2Nth1MKAfoxFlpZjgM8UyevgDffVjGPLvjFC8YjkVPsvUwYoa6x6tmYe2h7Aw38Fl4HQJNMHHGNCZpk05xpxMgLYznJnPakyuxnxVkxXHPxTfpr-xK_f_bYeLv0HzcH-5VHwA00mdlQ |
CitedBy_id | crossref_primary_10_1111_trf_18055 crossref_primary_10_1182_blood_2023022593 crossref_primary_10_1182_hematology_2022000379 crossref_primary_10_1080_17474086_2023_2209716 crossref_primary_10_3389_fpubh_2024_1365433 |
Cites_doi | 10.1182/blood-2017-01-759258 10.1111/bjh.14423 10.1111/tme.12312 10.1111/j.1537-2995.2008.01746.x 10.1111/j.1423-0410.1986.tb04849.x 10.1111/trf.12001 10.1111/j.1537-2995.2011.03402.x 10.1111/j.1538-7836.2011.04317.x 10.1111/j.1537-2995.2005.04344.x 10.1182/blood.V64.2.406.406 10.1056/NEJMoa1807320 10.1056/NEJMoa0904084 10.3389/fbioe.2018.00099 10.1111/trf.15036 10.1073/pnas.93.21.11877 10.1056/NEJMoa1212772 10.1016/S2352-3026(20)30186-1 10.1046/j.1365-2141.1997.1572983.x 10.7326/M14-1589 10.1016/S0140-6736(16)30392-0 10.1182/blood-2014-12-617159 10.1046/j.1537-2995.1997.37197176945.x 10.1111/j.1537-2995.2006.00895.x |
ContentType | Journal Article |
Copyright | 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland. 2022 AABB |
Copyright_xml | – notice: 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland. – notice: 2022 AABB |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7U9 8FD FR3 H94 K9. P64 7X8 |
DOI | 10.1111/trf.16723 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-2995 |
EndPage | 182 |
ExternalDocumentID | 34757639 10_1111_trf_16723 TRF16723 |
Genre | article Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1OB 1OC 29Q 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBNA ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ H~9 IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI TWZ UB1 UCJ V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WUP WVDHM WXI WXSBR X7M XG1 YFH YQI YQJ YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION CGR CUY CVF ECM EIF NPM 7QO 7U9 8FD FR3 H94 K9. P64 7X8 |
ID | FETCH-LOGICAL-c3533-d6e0b7d0b7b560856b7ad2eba9842b1af50da3df21ad2747fa36127aff702f333 |
IEDL.DBID | DR2 |
ISSN | 0041-1132 1537-2995 |
IngestDate | Fri Sep 05 11:03:10 EDT 2025 Wed Aug 13 03:09:09 EDT 2025 Mon Jul 21 06:04:19 EDT 2025 Wed Oct 01 00:48:48 EDT 2025 Thu Apr 24 22:57:46 EDT 2025 Wed Jan 22 16:26:35 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | dose storage lesion platelets |
Language | English |
License | 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3533-d6e0b7d0b7b560856b7ad2eba9842b1af50da3df21ad2747fa36127aff702f333 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-6459-1637 |
PMID | 34757639 |
PQID | 2619063918 |
PQPubID | 1096380 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2596021860 proquest_journals_2619063918 pubmed_primary_34757639 crossref_citationtrail_10_1111_trf_16723 crossref_primary_10_1111_trf_16723 wiley_primary_10_1111_trf_16723_TRF16723 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2022 2022-01-00 20220101 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 01 year: 2022 text: January 2022 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Bethesda |
PublicationTitle | Transfusion (Philadelphia, Pa.) |
PublicationTitleAlternate | Transfusion |
PublicationYear | 2022 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2015; 162 2020; 7 2018; 6 1984; 64 1986; 50 2015; 126 2006; 46 1997; 98 2020 1997; 37 2013; 368 2019; 59 2013; 53 1996; 93 2008; 48 2016; 387 2010; 362 2017; 130 2017; 176 2019; 380 2016; 26 2005; 45 2012; 52 2011; 9 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 Galloway‐Haskins R (e_1_2_9_9_1) 2013; 53 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 AABB (e_1_2_9_4_1) 2020 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_25_1 EQDM (e_1_2_9_6_1) 2020 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
References_xml | – volume: 6 year: 2018 article-title: Blood‐contacting biomaterials: in vitro evaluation of the hemocompatibility publication-title: Front Bioeng Biotechnol – volume: 52 start-page: 810 issue: 4 year: 2012 end-page: 8 article-title: Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services publication-title: Transfusion – volume: 380 start-page: 242 issue: 3 year: 2019 end-page: 51 article-title: Randomized trial of platelet‐transfusion thresholds in neonates publication-title: N Engl J Med – volume: 50 start-page: 71 issue: 2 year: 1986 end-page: 7 article-title: Morphological changes associated with pH changes during storage of platelet concentrates in first‐generation 3‐day container publication-title: Vox Sang – volume: 26 start-page: 177 issue: 3 year: 2016 end-page: 85 article-title: I am the 9%: making the case for whole‐blood platelets publication-title: Transfus Med – volume: 130 start-page: 214 issue: 2 year: 2017 end-page: 20 article-title: The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial publication-title: Blood – volume: 126 start-page: 1017 issue: 8 year: 2015 end-page: 26 article-title: Single platelets seal neutrophil‐induced vascular breaches via GPVI during immune‐complex‐mediated inflammation in mice publication-title: Blood – volume: 362 start-page: 600 issue: 7 year: 2010 end-page: 13 article-title: Dose of prophylactic platelet transfusions and prevention of hemorrhage publication-title: N Engl J Med – volume: 53 start-page: 1780 issue: 8 year: 2013 end-page: 7 article-title: Flow cytometric assessment of agonist‐induced P‐selectin expression as a measure of platelet quality in stored platelet concentrates publication-title: Transfusion – volume: 48 start-page: 1669 issue: 8 year: 2008 end-page: 75 article-title: The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days publication-title: Transfusion – volume: 7 start-page: e756 issue: 10 year: 2020 end-page: e64 article-title: Effects of the COVID‐19 pandemic on supply and use of blood for transfusion publication-title: Lancet Haematol – volume: 368 start-page: 1771 issue: 19 year: 2013 end-page: 80 article-title: A no‐prophylaxis platelet‐transfusion strategy for hematologic cancers publication-title: N Engl J Med – volume: 64 start-page: 406 issue: 2 year: 1984 end-page: 14 article-title: Platelet metabolism during storage of platelet concentrates at 22 degrees C publication-title: Blood – volume: 387 start-page: 2605 issue: 10038 year: 2016 end-page: 13 article-title: Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open‐label, phase 3 trial publication-title: Lancet – volume: 93 start-page: 11877 issue: 21 year: 1996 end-page: 82 article-title: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P‐selectin but continue to circulate and function publication-title: Proc Natl Acad Sci U S A – volume: 37 start-page: 12 issue: 1 year: 1997 end-page: 7 article-title: The expression of p‐selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability publication-title: Transfusion – volume: 53 year: 2013 article-title: Platelet dosing, suspension medium and inter‐transfusion interval publication-title: Tranfusion – volume: 45 start-page: 773 issue: 5 year: 2005 end-page: 8 article-title: The value of pH as a quality control indicator for apheresis platelets publication-title: Transfusion – year: 2020 – volume: 46 start-page: 1300 issue: 8 year: 2006 end-page: 5 article-title: In vitro pH effects on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative publication-title: Transfusion – volume: 59 start-page: 779 issue: 2 year: 2019 end-page: 88 article-title: The argument(s) for lowering the US minimum required content of apheresis platelet components publication-title: Transfusion – volume: 98 start-page: 86 issue: 1 year: 1997 end-page: 95 article-title: Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods publication-title: Br J Haematol – volume: 176 start-page: 365 issue: 3 year: 2017 end-page: 94 article-title: Guidelines for the use of platelet transfusions publication-title: Br J Haematol – volume: 9 start-page: 56 issue: Suppl 1 year: 2011 end-page: 65 article-title: How platelets safeguard vascular integrity publication-title: J Thromb Haemost – volume: 162 start-page: 205 issue: 3 year: 2015 end-page: 13 article-title: Platelet transfusion: a clinical practice guideline from the AABB publication-title: Ann Intern Med – ident: e_1_2_9_21_1 doi: 10.1182/blood-2017-01-759258 – volume-title: Guide to the preparation, use and quality assurance of blood components year: 2020 ident: e_1_2_9_6_1 – ident: e_1_2_9_10_1 doi: 10.1111/bjh.14423 – ident: e_1_2_9_31_1 – volume: 53 start-page: S53‐030H0 year: 2013 ident: e_1_2_9_9_1 article-title: Platelet dosing, suspension medium and inter‐transfusion interval publication-title: Tranfusion – ident: e_1_2_9_11_1 doi: 10.1111/tme.12312 – ident: e_1_2_9_25_1 doi: 10.1111/j.1537-2995.2008.01746.x – ident: e_1_2_9_13_1 doi: 10.1111/j.1423-0410.1986.tb04849.x – ident: e_1_2_9_18_1 doi: 10.1111/trf.12001 – ident: e_1_2_9_19_1 doi: 10.1111/j.1537-2995.2011.03402.x – ident: e_1_2_9_24_1 doi: 10.1111/j.1538-7836.2011.04317.x – ident: e_1_2_9_15_1 doi: 10.1111/j.1537-2995.2005.04344.x – ident: e_1_2_9_16_1 doi: 10.1182/blood.V64.2.406.406 – ident: e_1_2_9_29_1 doi: 10.1056/NEJMoa1807320 – volume-title: Standards for blood banks and transfusion services year: 2020 ident: e_1_2_9_4_1 – ident: e_1_2_9_27_1 doi: 10.1056/NEJMoa0904084 – ident: e_1_2_9_12_1 doi: 10.3389/fbioe.2018.00099 – ident: e_1_2_9_2_1 – ident: e_1_2_9_7_1 doi: 10.1111/trf.15036 – ident: e_1_2_9_22_1 doi: 10.1073/pnas.93.21.11877 – ident: e_1_2_9_28_1 doi: 10.1056/NEJMoa1212772 – ident: e_1_2_9_5_1 – ident: e_1_2_9_8_1 – ident: e_1_2_9_3_1 doi: 10.1016/S2352-3026(20)30186-1 – ident: e_1_2_9_17_1 doi: 10.1046/j.1365-2141.1997.1572983.x – ident: e_1_2_9_26_1 doi: 10.7326/M14-1589 – ident: e_1_2_9_30_1 doi: 10.1016/S0140-6736(16)30392-0 – ident: e_1_2_9_23_1 doi: 10.1182/blood-2014-12-617159 – ident: e_1_2_9_20_1 doi: 10.1046/j.1537-2995.1997.37197176945.x – ident: e_1_2_9_14_1 doi: 10.1111/j.1537-2995.2006.00895.x |
SSID | ssj0002901 |
Score | 2.3854215 |
Snippet | Background
The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the... The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational... BackgroundThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 173 |
SubjectTerms | ABO system Apheresis Bags Blood Blood platelets Blood Platelets - metabolism Blood Preservation Contingency COVID-19 dose Humans Markers Pandemics pH effects Platelet Count Plateletpheresis Platelets Production methods Quality assessment Shortages Splitting Storage Storage containers storage lesion |
Title | Evaluating apheresis platelets at reduced dose as a contingency measure for extreme shortages |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.16723 https://www.ncbi.nlm.nih.gov/pubmed/34757639 https://www.proquest.com/docview/2619063918 https://www.proquest.com/docview/2596021860 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0041-1132 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1537-2995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002901 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hDhWXFuhrKSCDeuglq9iOk6w4VYgVqgQHBBKHVpGftCrNok32AL--M86jpQ-p6iFSlIxlx_bE38x4PgO8TbVwVpUuyXIRksy5kJRWukTOJOee6Fw05TufneenV9mHa3W9BkdDLkzHDzE63Egz4v-aFFyb5iclb5dhyvNCENMnlyqGaC9-UEdRfLCLLvOETlPvWYVoF89Y8vFa9BvAfIxX44IzfwYfh6Z2-0y-TletmdqHX1gc__NbNuFpD0TZ-27mbMGar7fhyVkfan8On056HvD6hmniHvDNl4bd3SI2xaFumG7ZkmhfvWNu0Xim8RGjje8xW8ves2-d95EhKma4ApAfkjWfCe3f-OYFXM1PLo9Pk_4shsRKRISJy31qCoeXQYxUqtwU2glv9KzMhOE6qNRp6YLg-BhNlKAlYqdCh1CkIkgpX8J6vaj9a2BYUNnUGseVR-NwRox6hdLcWxNEZrIJvBtGpbI9UTmdl3FbDQYLdlcVu2sCh6PoXcfO8Seh3WFoq15Bm4oMR0JnvJzAwfgaVYviJbr2ixXKKDTv6MyudAKvuikx1iKzAi01OcPGxoH9e_XV5cU83uz8u-gb2BCUZhFdPbuw3i5Xfg_BT2v24yz_DmpUAJw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVoJeaHmVpS01iAOXrGI7r5W4VNDVAt0eqq3USxX5WRAlW22yB_j1zOTVF5UQh0hRYsuOxxN_M2N_A_AuVMKaOLNBlAgfRNb6IDPSBnIkOXdE56LovPP0KJmcRF9O49MV-NCdhWn4IXqHG2lG_b8mBSeH9DUtrxZ-yJNUyAewRvE5UstPx1fkURQhbOLLPKB86i2vEO3j6aveXI3uQMybiLVecsYbcNZ1ttlp8mO4rPTQ_L7F4_i_X7MJj1ssyvabyfMEVlzxFB5O22j7Mzg7aKnAi3OmiH7Ald9LdnmB8BSlXTJVsQUxvzrL7Lx0TOEjRnvf6wNb5hf72TggGQJjhosAuSJZ-Y0A_7krn8PJ-GD2cRK06RgCIxEUBjZxoU4tXhphUhYnOlVWOK1GWSQ0Vz4OrZLWC46P0UrxSiJ8SpX3aSi8lPIFrBbzwr0EhhVjExpteezQPhwRqV4aK-6M9iLS0QDed2LJTctVTikzLvLOZsHhyuvhGsDbvuhlQ9Dxt0I7nWzzVkfLnGxHAmg8G8Cb_jVqF4VMVOHmSywTo4VHabvCAWw1c6JvRUYpGmtyhJ2tJXt_8_nseFzfvPr3onvwaDKbHuaHn4--bsO6oFMXtednB1arxdLtIhaq9Ot6yv8BaX8EuA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkFAvFPrcFqhb9dBLVrGd14oTAlbQAqoQSBxaRX7SCppdbbKH9tczkxePUqnqIVKU2LLj8cTfzNjfAHwIlbAmzmwQJcIHkbU-yIy0gRxJzh3RuSg673x0nOyfRZ_O4_MF2OrOwjT8EL3DjTSj_l-Tgk-tv6Xk1cwPeZIK-QiWogStK0JEJzfcURQgbMLLPKB06i2tEG3j6aveXYz-QJh3AWu94oyfwNeur81Gk8vhvNJD8_sejeN_fswqrLRIlG03U2cNFlzxFJaP2lj7M_i21xKBFxdMEfmAK3-UbHqF4BRlXTJVsRnxvjrL7KR0TOEjRjvf6-Na5hf72bgfGcJihksAOSJZ-Z3g_oUrn8PZeO90Zz9okzEERiIkDGziQp1avDSCpCxOdKqscFqNskhornwcWiWtFxwfo43ilUTwlCrv01B4KeULWCwmhXsFDCvGJjTa8tihdTgiSr00VtwZ7UWkowF87KSSm5apnBJmXOWdxYLDldfDNYD3fdFpQ8_xUKH1TrR5q6FlTpYjwTOeDeBd_xp1iwImqnCTOZaJ0b6jpF3hAF42U6JvRUYpmmpyhJ2tBfv35vPTk3F98_rfi76F5S-74_zw4PjzG3gs6MhF7fZZh8VqNncbCIQqvVlP-Gte7QNn |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+apheresis+platelets+at+reduced+dose+as+a+contingency+measure+for+extreme+shortages&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Smethurst%2C+Peter+A&rft.au=McAndrew%2C+Margaret&rft.au=Proffitt%2C+Susan&rft.au=Procter%2C+Simon&rft.date=2022-01-01&rft.eissn=1537-2995&rft.volume=62&rft.issue=1&rft.spage=173&rft_id=info:doi/10.1111%2Ftrf.16723&rft_id=info%3Apmid%2F34757639&rft.externalDocID=34757639 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon |